Glaucoma Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

Glaucoma Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

The global glaucoma therapeutics market size reached US$ 7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 10.2 Billion by 2027, exhibiting a growth rate (CAGR) of 6.52% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Glaucoma therapeutics refers to various treatment alternatives for primary open-angle (POA) and primary angle-closure (PAC) glaucoma. The disease is characterized by structural changes in the optic nerves that usually lead to visual loss and blindness. The treatment for glaucoma can be initiated through topical eye drops, which majorly consist of beta-blockers, prostaglandin analogs, cholinergic, carbonic anhydrase inhibitors and alpha-adrenergic agonists. These eye drops minimize the production of fluid in the eyes, thereby reducing the intraocular pressure (IOP). This can be followed by traditional or laser surgical procedures or a combination of both, which use products such as implantable extended-release devices, polymer-based contact lenses, drug-eluting punctal plugs, microneedle-injection devices and micro-dosing technologies.

The increasing prevalence of glaucoma across the globe represents one of the key factors driving the growth of the market. Glaucoma is highly prevalent in patients with diabetes and other eye disorders, such as age-related macular degeneration (AMD), cataract and dry eye. In line with this, the rising geriatric population, which is more susceptible to such ailments, is creating a positive outlook for the market growth. Furthermore, increasing health consciousness among the masses and rising preference for laser glaucoma surgery is also driving the market growth. Additionally, the development of innovative combination dugs is acting as another growth-inducing factor. Pharmaceutical manufacturers are creating anti-glaucoma drugs and prostaglandin analogs combined with two or more drugs to control the elevated levels of IOP. Other factors, including the advent of advanced glaucoma diagnostic techniques, along with improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global glaucoma therapeutics market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, indication and end user.

Breakup by Drug Class:

Prostaglandin Analogs
Beta Blockers
Alpha Adrenergic Agonists
Carbonic Anhydrase Inhibitors
Combination Drugs
Others

Breakup by Indication:

Open Angle Glaucoma
Angle Closure Glaucoma
Others

Breakup by End User:

Hospitals
Ophthalmic Clinics
Ambulatory Surgery Centers
Others

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Aerie Pharmaceuticals Inc., Allergan Plc, Bausch & Lomb Incorporated (Bausch Health Companies Inc.), Inotek Pharmaceuticals Corp., Merck & Co. Inc., Novartis AG, Pfizer Inc., Santen Pharmaceutical Co. Ltd., SIFI S.p.A and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:
How has the global glaucoma therapeutics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global glaucoma therapeutics market?
What are the key regional markets?
What is the breakup of the market based on the drug class?
What is the breakup of the market based on the indication?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global glaucoma therapeutics market and who are the key players?
What is the degree of competition in the industry?